Psychometric properties of a Spanish-version of the Schizophrenia Objective Functioning Instrument (Sp-SOFI)

  1. Susana Al-Halabí 1
  2. Pilar A. Sáiz 2
  3. Marlén Garrido 3
  4. Gonzalo Galván 4
  5. María José Casares 5
  6. María Teresa Bobes-Bascarán 1
  7. Eva M. Díaz-Mesa 1
  8. Patricia Burón 1
  9. Leticia García-Álvarez 1
  10. Javier Suárez-Álvarez 2
  11. José Muñiz 2
  12. M. Paz García-Portilla 2
  13. Julio Bobes 2
  1. 1 Centro de Investigacion Biomedica en Red de Salud Mental
    info

    Centro de Investigacion Biomedica en Red de Salud Mental

    Madrid, España

    ROR https://ror.org/009byq155

  2. 2 Universidad de Oviedo
    info

    Universidad de Oviedo

    Oviedo, España

    ROR https://ror.org/006gksa02

  3. 3 Instituto Universitario de Neurociencias del Principado de Asturias
  4. 4 Universidad Cooperativa de Colombia
    info

    Universidad Cooperativa de Colombia

    Bogotá, Colombia

    ROR https://ror.org/04td15k45

  5. 5 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

Mostrar afiliaciones +
Revista:
International journal of clinical and health psychology

ISSN: 1697-2600

Año de publicación: 2016

Volumen: 16

Número: 1

Páginas: 58-75

Tipo: Artículo

DOI: 10.1016/J.IJCHP.2015.07.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: International journal of clinical and health psychology

Objetivos de desarrollo sostenible

Resumen

The Schizophrenia Objective Functioning Instrument (SOFI) is an interviewer-administered scale designed to objectively assess the actual level of patient functioning and to measure community functioning related to cognitive impairment and psychopathology. The aim was to examine the psychometric properties of the Spanish version of the SOFI (Sp-SOFI) in a sample of 155 Spanish outpatients with schizophrenia disorder. The instruments applied were Sp-SOFI, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Personal and Social Performance Scale (PSP), and Global Assessment of Functioning (GAF). The discrimination indexes of the Sp-SOFI items range from .21 to .77. Exploratory factor analysis showed an essentially one-dimensional structure. Cronbach's alpha was .93. Test-retest reliability for the Sp-SOFI total score was .87 (p < .001). The canonical correlation between SP-SOFI domains and PSP dimensions was .83. The multiple correlation coefficient between Sp-SOFI domains and GAF score was .84. Sp-SOFI scores were significantly different between high and low scores on the PANSS scales (p < .001). Sp-SOFI measures discriminated among patients with doubtful, mild, moderate, and severe schizophrenia disorder according to CGI-SCH scales (p < .001). New evidence about the validity of the SOFI was provided. The Sp-SOFI is a reliable and valid tool for using in clinical practice.

€ Ver financiación

Información de financiación

This study was supported by the Instituto de Salud Carlos III , Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.

Financiadores

Referencias bibliográficas

  • American Psychiatric Association APA. (1987). Diagnostic and Sta-tistical Manual on Mental disorders: DSM-III-R. Washington, D.C:APA.
  • American Psychological Association, APA (2015). Recognizingthe sings of schizophrenia. Retrieved 20/03/2015, fromhttp://apa.org/helpcenter/recognizing-schizophrenia.aspx
  • Carretero-Dios, H., & Pérez, C. (2007). Standards for the develop-ment and review of instrumental studies: Considerations abouttest selection in psychological research. International Journalof Clinical and Health Psychology, 7, 863---882.
  • Chisolm, T. H., Abrams, H. B., McArdle, R., Wilson, R. H., & Doyle,P. J. (2005). The WHO-DAS II: Psychometric properties in themeasurement of functional health status in adults with acquiredhearing loss. Trends in Amplification, 9, 111---126.
  • European Federation of Psychologists’ Associations, EFPA(2014). We need to let psychologist intervene sooner toreduce the risk of developing schizophrenia. Retrieved20/03/2015, from http://www.efpa.eu/news/we-need-to-let-psychologist-intervene-sooner-to-reduce-the-risk-of-developing-schizophrenia
  • European Medicines Agency, EMEA (2005). Reflection paperon the regulatory guidance for the use of health-relatedquality of life (HRQL) measures in the evaluation of medic-inal products. Retrieved 20/03/2015, from http://www.ispor.org/workpaper/emea-hrql-guidance.pdf
  • Evers, A., Muñiz, J., Hagemeister, C., Høstmælingen, A., Lindley, P.,Sjöberg, A., & Bartram, D. (2013). Assessing the quality of tests:Revision of the EFPA review model. Psicothema, 25, 293---301.
  • García-Portilla, M. P., & Bobes, J. (2013). The new challenge inidentifying the negative syndrome of schizophrenia. Revista dePsiquiatría y Salud Mental, 6, 141---143.
  • García-Portilla, M. P., García-Álvarez, L., Saiz, P. A., Al-Halabí, S.,Bobes-Bascarán, M. T., Bascarán, M. T., Muñiz, J., & Bobes, J.(2015). Psychometric evaluation of the negative syndrome ofschizophrenia. European Archives of Psychiatry Clinical Neuro-science., http://dx.doi.org/10.1007/s00406-015-0595-z
  • García-Portilla, M. P., Gomar, J. J., Bobes-Bascarán, M. T.,Menendez-Miranda, I., Sáiz, P. A., Muñiz, J., Arango, C.,Patterson, T. L., Harvey, P. D., Bobes, J., & Goldberg, T. E.(2013). Validation of a European Spanish-version of the Univer-sity of California performance Skills Assessment (Sp-UPSA) inpatients with schizophrenia and bipolar disorder. SchizophreniaResearch, 150, 421---426.
  • García-Portilla, M. P., Gomar, J. J., Bobes-Bascaran, M. T.,Menéndez-Miranda, I., Saiz, P. A., Muñiz, J., Arango, C.,Patterson, T. L., Harvey, P. D., Bobes, J., & Goldberg, T. E.(2014). Development of the Spanish Brief-version of the Univer-sity of California Performance Skills Assessment (Sp-UPSA-Brief)in patients with schizophrenia and bipolar disorder. Revista dePsiquiatría y Salud Mental, 7, 113---120.
  • García-Portilla, M. P., Saiz, P. A., Bousoño, M., Bascarán, M. T.,Guzmán-Quilo, C., & Bobes, J. (2011). Validation of the Span-ish, from Spain, Personal and Social Performance scale (PSP) inoutpatients with stable and unstable schizophrenia. Revista dePsiquiatría y Salud Mental, 4, 9---18.
  • Gavilán, J. M., & García-Albea, J. E. (2014). La función ejecutivaen la esquizofrenia y su asociación con las habilidades cognitivassociales (mentalistas). Revista de Psiquiatría y Salud Mental.,http://dx.doi.org/10.1016/j.rpsm.2014.01.008
  • Gómez-Benito, J., Guilera, G., Pino, O., Tabarés-Seisdedos, R., &Marínez-Arán, A. (2014). Comparing neurocognitive impairmentin schizophrenia and bipolar I disorder using the Screen for Cog-nitive Impairment in Psychiatry Scale. International Journal ofClinical and Health Psychology, 14, 128---136.
  • Gómez-Benito, J., Hidalgo, M., & Zumbo, B. (2013). Effectivenessof combining statistical tests and effect sizes when using logis-tic discriminant function regression to detect differential itemfunctioning for polytomous items. Educational and PsychologicalMeasurement, 73, 857---897.
  • Green, M. F., & Harvey, P. D. (2014). Cognition in schizophrenia:Past, present, and future. Schizophrenia Research: Cognition,1, 1---9.
  • Green, M. F., Kern, R. S., Braff, D. L., & Mints, J. (2000). Neu-rocognitive deficits and functional outcome in schizophrenia:Are we measuring the ‘‘right stuff’’? Schizophrenia Bulletin, 26,119---136.
  • Haro, J. M., Kamath, S. A., Ochoa, S., Novick, D., Rele, K.,Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A.,Araya, S., Gervin, M., Alonso, J., Mavreas, V., Lavrentzou, E.,Liontos, N., Gregor, K., Jones, P. B., & SOHO Study Group.(2003). Clinical Global Impression-Schizophrenia scale: A sim-ple instrument to measure the diversity of symptoms present inschizophrenia. Acta Psychiatrica Scandinavica, 107(Suppl. 416),6---23.
  • ICF Research Branch (2015). ICF Core Set for Schizophrenia.Retrieved 20/06/2015, from http://www.icf-research-branch.org/icf-core-sets-projects2/mental-health/icf-core-set-for-schizophrenia
  • Kay, S., Fiszbein, A., & Opler, L. (1987). The Positive and Nega-tive Syndrome Scale (PANSS) for schizophrenia. SchizophreniaBulletin, 13, 262---276.
  • Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R.,Dugar, A., Zivkov, M., & Stewart, M. (2013). Clinical trials ofpotential cognitive-enhancing drugs in schizophrenia: What havewe learned do far? Schizophrenia Bulletin, 39, 417---435.
  • Kleinman, L., Lieberman, J., Dube, S., Mohs, R., Zhao, Y., Kinon, B.,Carpenter, W., Harvey, P. D., Green, M. F., Keefe, R. S., Frank, L.,Bowman, L., & Revicki, D. A. (2009). Development and psycho-metric performance of the schizophrenia objective functioninginstrument: An interviewer administered measure of function.Schizophrenia Research, 107, 275---285.
  • Kline, R. B. (2005). Principles and practice of structural equationmodeling. New York: Guilford Press.
  • Lin, C. H., Huang, C. L., Chang, Y. C., Chen, P. W., Lin, C. Y., Tsai,G. E., & Lane, H. Y. (2013). Clinical symptoms, mainly negativesymptoms, mediate the influence of neurocognition and socialcognition on functional outcome of schizophrenia. SchizophreniaResearch, 146, 231---237.
  • Menéndez-Miranda, I., García-Portilla, M. P., García-Alvarez,L., Arrojo, M., Sanchez, P., Sarramea, F., Gomar, J.,Bobes-Bascarán, M. T., Sierra, P., Saiz, P., & Bobes, J. (2015).Predictive factors of functional capacity and real-world func-tioning in patients with schizophrenia. European Psychiatry, doi:http://dx.doi.org/10.1016/j.eurpsy.2014.12.011.
  • Montero, I., & León, G. O. (2007). A guide for naming research stud-ies in Psychology. International Journal of Clinical and HealthPsychology, 7, 847---862.
  • Muñiz, J., Elosua, P., & Hambleton, R. K. (2013). Directrices parala traducción y adaptación de los test: segunda edición. Psi-cothema, 25, 51---57.
  • Muñiz, J., Fidalgo, A. M., García-Cueto, E., Martínez, R., & Moreno,R. (2005). Análisis de los ítems. Madrid: La Muralla.
  • World Health Organization, WHO (2013). Comprehensive men-tal health action plan 2013-2020. Retrieved 28/01/2015, fromhttp://www.who.int/mental health/action plan 2013/en/
  • World Medical Association (2000). Declaration of Helsinki.Ethical Principles for Medical Research Involving Human Sub-jects. Retrieved 23/01/2015, from http://www.wma.net/en/20activities/10ethics/10helsinki/.
Fuente de los datos: Dialnet